Premium
En Route to New Therapeutic Options for Iron Overload Diseases: Matriptase‐2 as a Target for Kunitz‐Type Inhibitors
Author(s) -
Beckmann AnnaMadeleine,
Maurer Eva,
Lülsdorff Verena,
Wilms Annika,
Furtmann Norbert,
Bajorath Jürgen,
Gütschow Michael,
Stirnberg Marit
Publication year - 2016
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.201500651
Subject(s) - chemistry , serine protease , proteases , cell , protease , hepcidin , microbiology and biotechnology , biochemistry , enzyme , biology , immunology , inflammation
The cell‐surface serine protease matriptase‐2 is a critical stimulator of iron absorption by negatively regulating hepcidin, the key hormone of iron homeostasis. Thus, it has attracted much attention as a target in primary and secondary iron overload diseases. Here, we have characterised Kunitz‐type inhibitors hepatocyte growth factor activator inhibitor 1 (HAI‐1) and HAI‐2 as powerful, slow‐binding matriptase‐2 inhibitors. The binding modes of the matriptase‐2–HAI complexes were suggested by molecular modelling. Different assays, including cell‐free and cell‐based measurements of matriptase‐2 activity, determination of inhibition constants and evaluation of matriptase‐2 inhibition by analysis of downstream effects in human liver cells, demonstrated that matriptase‐2 is an excellent target for Kunitz inhibitors. In particular, HAI‐2 is considered a promising scaffold for the design of potent and selective matriptase‐2 inhibitors.